<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36978360</PMID><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2079-6382</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Antibiotics (Basel, Switzerland)</Title><ISOAbbreviation>Antibiotics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Consequences of Contracting COVID-19 or Taking the COVID-19 Vaccine for Individuals with a History of Lyme Disease.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">493</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/antibiotics12030493</ELocationID><Abstract><AbstractText>Individuals with Lyme disease can be very symptomatic. This survey compares the burden of illness for individuals with a history of Lyme disease (HLD) with individuals with a HLD who have either contracted COVID-19 or who have taken the COVID-19 vaccine. The findings describe the relative symptom burden among these three groups using a cross-sectional descriptive survey investigating the burden of Lyme disease in a pandemic. The survey includes the General Symptom Questionnaire-30 (GSQ-30), a brief self-report scale designed to assess the symptom burden in Lyme disease (LD). The results of this survey show that the overall burden of illness among individuals with HLD is not significantly different after contracting COVID-19 or after COVID-19 vaccination. A new survey will be needed to better understand why one in five individuals with a HLD reported long COVID after contracting COVID-19. These results should help clinicians and their patients to discuss the consequences of contracting a COVID-19 infection or being vaccinated against COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cameron</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Northern Westchester Hospital, Mt. Kisco, New York, NY 10549, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McWhinney</LastName><ForeName>Sean R</ForeName><Initials>SR</Initials><Identifier Source="ORCID">0000-0003-2029-810X</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, Dalhousie University, Halifax, NS B3H 2E2, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Antibiotics (Basel)</MedlineTA><NlmUniqueID>101637404</NlmUniqueID><ISSNLinking>2079-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">Lyme disease</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36978360</ArticleId><ArticleId IdType="pmc">PMC10044022</ArticleId><ArticleId IdType="doi">10.3390/antibiotics12030493</ArticleId><ArticleId IdType="pii">antibiotics12030493</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Logigian E.L., Kaplan R.F., Steere A.C. Chronic neurologic manifestations of Lyme disease. N. Engl. J. Med. 1990;323:1438&#x2013;1444. doi: 10.1056/NEJM199011223232102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199011223232102</ArticleId><ArticleId IdType="pubmed">2172819</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallon B.A., Keilp J.G., Corbera K.M., Petkova E., Britton C.B., Dwyer E., Slavov I., Cheng J., Dobkin J., Nelson D.R., et al. A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology. 2008;70:992&#x2013;1003. doi: 10.1212/01.WNL.0000284604.61160.2d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000284604.61160.2d</ArticleId><ArticleId IdType="pubmed">17928580</ArticleId></ArticleIdList></Reference><Reference><Citation>Halperin J.J., Little B.W., Coyle P.K., Dattwyler R.J. Lyme disease: Cause of a treatable peripheral neuropathy. Neurology. 1987;37:1700&#x2013;1706. doi: 10.1212/WNL.37.11.1700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.37.11.1700</ArticleId><ArticleId IdType="pubmed">3670609</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallon B.A., Nields J.A. Lyme disease: A neuropsychiatric illness. Am. J. Psychiatry. 1994;151:1571&#x2013;1583. doi: 10.1176/ajp.151.11.1571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/ajp.151.11.1571</ArticleId><ArticleId IdType="pubmed">7943444</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigra S., Hesselmark E., Bejerot S. Treatment of PANDAS and PANS: A systematic review. Neurosci. Biobehav. Rev. 2018;86:51&#x2013;65. doi: 10.1016/j.neubiorev.2018.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neubiorev.2018.01.001</ArticleId><ArticleId IdType="pubmed">29309797</ArticleId></ArticleIdList></Reference><Reference><Citation>Muehlenbachs A., Bollweg B.C., Schulz T.J., Forrester J.D., Carnes M.D., Molins C., Ray G.S., Cummings P.M., Ritter J.M., Blau D.M., et al. Cardiac Tropism of Borrelia burgdorferi: An Autopsy Study of Sudden Cardiac Death Associated with Lyme Carditis. Am. J. Pathol. 2016;186:1195&#x2013;1205. doi: 10.1016/j.ajpath.2015.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2015.12.027</ArticleId><ArticleId IdType="pubmed">26968341</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanjwal K., Karabin B., Kanjwal Y., Grubb B.P. Postural orthostatic tachycardia syndrome following Lyme disease. Cardiol. J. 2011;18:63&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">21305487</ArticleId></ArticleIdList></Reference><Reference><Citation>Maksimyan S., Syed M.S., Soti V. Post-Treatment Lyme Disease Syndrome: Need for Diagnosis and Treatment. Cureus. 2021;13:e18703. doi: 10.7759/cureus.18703.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.18703</ArticleId><ArticleId IdType="pmc">PMC8507427</ArticleId><ArticleId IdType="pubmed">34659931</ArticleId></ArticleIdList></Reference><Reference><Citation>Klempner M.S., Hu L.T., Evans J., Schmid C.H., Johnson G.M., Trevino R.P., Norton D., Levy L., Wall D., McCall J., et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 2001;345:85&#x2013;92. doi: 10.1056/NEJM200107123450202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200107123450202</ArticleId><ArticleId IdType="pubmed">11450676</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallon B.A., Zubcevik N., Bennett C., Doshi S., Rebman A.W., Kishon R., Moeller J.R., Octavien N.R., Aucott J.N. The General Symptom Questionnaire-30 (GSQ-30): A Brief Measure of Multi-System Symptom Burden in Lyme Disease. Front. Med. 2019;6:283. doi: 10.3389/fmed.2019.00283.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2019.00283</ArticleId><ArticleId IdType="pmc">PMC6908481</ArticleId><ArticleId IdType="pubmed">31867334</ArticleId></ArticleIdList></Reference><Reference><Citation>McAuliffe P., Brassard M.R., Fallon B. Memory and executive functions in adolescents with posttreatment Lyme disease. Appl. Neuropsychol. 2008;15:208&#x2013;219. doi: 10.1080/09084280802324473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09084280802324473</ArticleId><ArticleId IdType="pubmed">18726742</ArticleId></ArticleIdList></Reference><Reference><Citation>Logigian E.L., Kaplan R.F., Steere A.C. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J. Infect. Dis. 1999;180:377&#x2013;383. doi: 10.1086/314860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314860</ArticleId><ArticleId IdType="pubmed">10395852</ArticleId></ArticleIdList></Reference><Reference><Citation>Krupp L.B., Hyman L.G., Grimson R., Coyle P.K., Melville P., Ahnn S., Dattwyler R., Chandler B. Study and treatment of post Lyme disease (STOP-LD): A randomized double masked clinical trial. Neurology. 2003;60:1923&#x2013;1930. doi: 10.1212/01.WNL.0000071227.23769.9E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.WNL.0000071227.23769.9E</ArticleId><ArticleId IdType="pubmed">12821734</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiyegbusi O.L., Hughes S.E., Turner G., Rivera S.C., McMullan C., Chandan J.S., Haroon S., Price G., Davies E.H., Nirantharakumar K., et al. Symptoms, complications and management of long COVID: A review. J. R. Soc. Med. 2021;114:428&#x2013;442. doi: 10.1177/01410768211032850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/01410768211032850</ArticleId><ArticleId IdType="pmc">PMC8450986</ArticleId><ArticleId IdType="pubmed">34265229</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H., Raza S., Nowell J., Young M., Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. doi: 10.1136/bmj.n1648.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1648</ArticleId><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Ramirez D.C., Normand K., Zhaoyun Y., Torres-Castro R. Long-Term Impact of COVID-19: A Systematic Review of the Literature and Meta-Analysis. Biomedicines. 2021;9:900. doi: 10.3390/biomedicines9080900.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines9080900</ArticleId><ArticleId IdType="pmc">PMC8389585</ArticleId><ArticleId IdType="pubmed">34440104</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A., Khillan R., Mishra Y., Khurana S. The safety profile of COVID-19 vaccinations in the United States. Am. J. Infect. Control. 2022;50:15&#x2013;19. doi: 10.1016/j.ajic.2021.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajic.2021.10.015</ArticleId><ArticleId IdType="pmc">PMC8539830</ArticleId><ArticleId IdType="pubmed">34699960</ArticleId></ArticleIdList></Reference><Reference><Citation>Bates D., M&#xe4;chler M., Bolker B., Walker S. Fitting Linear Mixed-Effects Models Using lme4. J. Stat. Softw. 2015;67:1&#x2013;48. doi: 10.18637/jss.v067.i01.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v067.i01</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenth R.V. Emmeans: Estimated Marginal Means, Aka Least-Squares Means. 2021.  [(accessed on 1 January 2022)].  R Package Version 1.6.1. Available online:  https://CRAN.R-project.org/package=emmeans.</Citation></Reference><Reference><Citation>Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., Taverner T., Chandan J.S., Brown K., Simms-Williams N., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 2022;28:1706&#x2013;1714. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Aucott J.N., Soloski M.J., Rebman A.W., Crowder L.A., Lahey L.J., Wagner C.A., Robinson W.H., Bechtold K.T. CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: A Prospective Clinical Cohort Study. Clin. Vaccine Immunol. 2016;23:757&#x2013;766. doi: 10.1128/CVI.00071-16.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00071-16</ArticleId><ArticleId IdType="pmc">PMC5014924</ArticleId><ArticleId IdType="pubmed">27358211</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>